期刊文献+

miR-29a、ET-1在IgA肾病患者血清中的表达及其临床意义 被引量:1

Expressions and Clinical Significances of MiR-29a andET-1 in Serum of Patients with IgA Nephropathy
下载PDF
导出
摘要 目的探究微小RNA-29a(miR-29a)、内皮素-1(ET-1)在IgA肾病(IgAN)患者血清中的水平及其临床意义。方法选取2016年12月至2020年1月本院收治的IgAN患者78例进行研究(IgAN组),并选取同期体检健康者80例进行对照研究(正常组)。比较两组一般资料;实时荧光定量PCR(qRT-PCR)法检测血清miR-29a表达水平;酶联免疫吸附测定法(ELISA)测定血清ET-1水平;Pearson法分析IgAN患者血清miR-29a、ET-1水平与舒张压、收缩压、血清肌酐(SCr)、尿蛋白、肾小球滤过率(GFR),及miR-29a表达水平与ET-1的相关性;采用受试者工作特征曲线(ROC)评估血清miR-29a、ET-1对IgAN的预测价值。结果与正常组相比,IgAN组患者舒张压、收缩压、SCr、尿蛋白、血清ET-1水平均显著升高(P<0.05),GFR、血清miR-29a表达水平均明显降低(P<0.05);IgAN患者血清miR-29a表达水平与收缩压、SCr、尿蛋白呈负相关(P<0.05),与GFR呈正相关(P<0.05);IgAN患者血清ET-1水平与收缩压、SCr、尿蛋白呈正相关(P<0.05),与GFR呈负相关(P<0.05);血清miR-29a、ET-1预测IgAN的曲线下面积(AUC)分别为0.815、0.833,截断值分别为0.75、1.56 pmol/L,灵敏度分别为83.3%、84.6%,特异性分别为72.2%、72.2%;两者联合预测IgAN的AUC为0.880,灵敏度、特异性分别为82.1%、92.5%。结论IgAN患者血清miR-29a表达水平降低,ET-1水平升高,miR-29a、ET-1均可能在IgAN病理发展中起作用,两者联合可提高预测IgAN的价值,有利于临床筛查IgAN患者。 Objective To investigate the levels of serum microRNA-29a(miR-29a)and endothelin-1(ET-1)in patients with IgA nephropathy(IgAN)and their clinical significances.Methods 78 IgAN patients in our hospital from December,2016 to January,2020 were selected for the study(IgAN group),while 80 healthy people during the same period were selected for the control study(normal group).The general data of the two groups were compared.Real-time quantitative PCR(qRT-PCR)was conducted to detect the expression of miR-29a in serum and the level of serum ET-1 was measured by enzyme-linked immunosorbent assay(ELISA).Pearson method was applied to analyze the correlation between serum miR-29a,ET-1 and diastolic blood pressure,systolic blood pressure,serum creatinine(SCr),urinary protein,glomerular filtration rate(GFR),and the correlation between miR-29a and ET-1.Receiver operating characteristic curve(ROC)was drew to evaluate the diagnostic value of serum miR-29a and ET-1 in IgAN.Results ompared with those in the normal group,the diastolic blood pressure,systolic blood pressure,SCr,urinary protein and serum ET-1 levels in IgAN group were significantly higher(P<0.05),while GFR and serum miR-29a expression levels were significantly lower(P<0.05).The expression level of serum miR-29a in IgAN patients was negatively correlated with systolic blood pressure,SCr,and urine protein(P<0.05),but positively correlated with GFR(P<0.05).Serum ET-1 level in IgAN patients was positively correlated with systolic blood pressure,SCr,and urine protein(P<0.05),while negatively correlated with GFR(P<0.05).The area under the curve(AUC)of serum miR-29a and ET-1 in the diagnosis of IgAN were 0.815 and 0.833,with the cut-off value 0.75 and 1.56 pmol/L,respectively.The sensitivities were 83.3%and 84.6%,and the specificities were 72.2%and 72.2%,respectively.The AUC of the combined diagnosis was 0.880,with the sensitivity and specificity 82.1%and 92.5%,respectively.Conclusion The expression level of miR-29a in IgAN patients is decreased and the level of ET-1 is incre
作者 韩艳 高原小雪 谢宇端 HAN Yan;GAO Yuanxiaoxue;XIE Yuduan(Department of Laboratory Medicine,Wangjing Hospital,Chinese Academy of Traditional Chinese Medicine,Beijing 100102,China)
出处 《标记免疫分析与临床》 CAS 2021年第7期1095-1099,共5页 Labeled Immunoassays and Clinical Medicine
基金 中国中医科学院望京医院院级科研课题(编号:WJYY2018-13)。
关键词 微小RNA-29a 内皮素-1 IGA肾病 血清 诊断 MicroRNA-29a Endothelin-1 IgA nephropathy Serum Diagnosis
  • 相关文献

参考文献7

二级参考文献61

  • 1Li LS, Lui ZH. Epidemiologic data of renal diseases from a single unit in China analysis based on 13,519 renal biopsies [ J ]. Kidney Int, 2004, 66:920-923. 被引量:1
  • 2KDIGO Board Melnbers. KDIGO clinical practice guideline for glomeru- lonephritis. Kidney International Supplements, 2012 ( 2 ) : 209 -217. 被引量:1
  • 3Reich HN, Troyanov S, Scholey JW, et al. Remission of proteinuria improves prognosis in IgAN [ J]. J Am Soc Nephrol, 2007,18 ( 12 ) : 3177-3183. 被引量:1
  • 4Working Group of the International lgA Nephropathy Network and the Renal Pathology Society. The Oxford classification of IgA nephropathy : rationale, clinicopatho'logical correlations, and classification [ J ]. Kidney Int ,2009,6:534-545. 被引量:1
  • 5Park KS, Han SH, Kie JH, et al. Comparison of the Haas and the Oxford classifications for prediction of renal outcome in patients with IgA nephropathy [ J ]. Human Pathology,45:236-243. 被引量:1
  • 6Li PKT, Leung CB, Chow KM, et al. Hang Kong study using Valsartan in IgAN (HKVIN)-A double-blind randomized placebo-controlled study [ J ]. Am J Kidney Dis,2006,47 (5) :751-760. 被引量:1
  • 7Coppo R, Peruzzi L, Amore A, et al. IgACE: a placebo-controlled, randomized trial of angiotensin-converting enzyme inhibitors in children and young people with IgAN and moderate proteinuria [ J ]. J Am Soc Nephrol, 2007,18 ( 6 ) : 1880 - 1888. 被引量:1
  • 8Tang S, Leung JC, Chan LY, et al. Mycophenolate mofetil alleviates persistent proteinuria in IgA nephropathy [ J ]. Kidney Int, 2005,68 : 802-812. 被引量:1
  • 9Frisch G, Lin J, Rosenstock J, et al. Mycophenolate mofetil (MMF) vsplacebo in patients with moderately advanced IgA nephropathy: a double-blind randomized controlled trial [ J ]. Nephrol Dial Transplant, 2005,20:2139-2145. 被引量:1
  • 10Coppo R. Is a legacy effect possible in IgA nephropathy? [ J ]. Nephrology Dialysis Transplantation ,2013,28 (7) : 1657-1662. 被引量:1

共引文献88

同被引文献13

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部